Bind Therapeutics has agreed to three deals potentially worth a total of $1 billion to help drugmakers develop nanomedicine. Drugs incorporating nanoparticles of polymers, gold and graphene are in various stages of development, including 117 oncology drugs, according to Thomson Reuters Pharma. Nanoparticles may allow targeted treatment of tumors with fewer side effects than conventional therapies and may also be useful in drugs for inflammatory disorders, pain, and heart and brain diseases, as well as diagnostics.
Nanoparticles could have giant impact on drug development
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|